The influence of the CYP2C19*10 allele on clopidogrel activation and CYP2C19*2 genotyping.

ABSTRACT:

Background/objectives

The polymorphic hepatic enzyme CYP2C19 catalyzes the metabolism of clinically important drugs such as clopidogrel, proton-pump inhibitors, and others and clinical pharmacogenetic testing for clopidogrel is increasingly common. The CYP2C19*10 single-nucleotide polymorphism (SNP) is located 1 bp upstream the CYP2C19*2 SNP. Despite the low frequency of the CYP2C19*10 allele, its impact on metabolism of CYP2C19 substrates and CYP2C19*2 genotyping makes it an important SNP to consider for pharmacogenetic testing of CYP2C19. However, the effect of the CYP2C19*10 allele on clopidogrel metabolism has not been explored to date.

Methods

We measured the enzymatic activity of the CYP2C19.10 protein against clopidogrel. DNA samples from two clinical studies were gen

SUBMITTER: Langaee TY 

PROVIDER: S-EPMC4090277 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature